Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Immunologic Deficiency Syndromes

ClinicalTrials.gov lists 7,565 trials for Immunologic Deficiency Syndromes or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 1,141.

MeSH D007153 Immune System Diseases C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,151 Phase 1/2 Phase 1/2 284 Phase 2 Phase 2 983 Phase 2/3 Phase 2/3 107 Phase 3 Phase 3 767 Phase 4 Phase 4 611 Not applicable Not applicable 2,091 Observational Observational 1,540 Phase 1 Phase 1 1,151 Phase 1/2 Phase 1/2 284 Phase 2 Phase 2 983 Phase 2/3 Phase 2/3 107 Phase 3 Phase 3 767 Phase 4 Phase 4 611 Not applicable Not applicable 2,091 Observational Observational 1,540

Trials per phase

1 more section with rows

204 of the 7,565 trials are tagged with Immunologic Deficiency Syndromes itself; the rest are tagged with a narrower condition beneath it.

Get the Immunologic Deficiency Syndromes report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Immunologic Deficiency Syndromes trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 21 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 346

1990: 7 trials (Observational 3, Phase 3 2, Phase 2 2) 1991: 4 trials (Phase 3 1, Phase 2 3) 1992: 11 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 2, Phase 1/2 1) 1993: 7 trials (Observational 5, Phase 2 2) 1994: 18 trials (Observational 8, Not applicable 4, Phase 4 2, Phase 2/3 1, Phase 1 3) 1995: 20 trials (Observational 6, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1 5) 1996: 19 trials (Observational 7, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1 2) 1997: 34 trials (Observational 10, Not applicable 5, Phase 3 6, Phase 2 3, Phase 1/2 3, Phase 1 7) 1998: 30 trials (Observational 10, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2 6, Phase 1 6) 1999: 74 trials (Observational 12, Not applicable 8, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 20, Phase 1/2 1, Phase 1 13) 2000: 77 trials (Other 1, Observational 23, Not applicable 8, Phase 4 4, Phase 3 18, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 8) 2001: 93 trials (Other 1, Observational 22, Not applicable 12, Phase 4 5, Phase 3 21, Phase 2/3 5, Phase 2 16, Phase 1/2 5, Phase 1 6) 2002: 138 trials (Other 1, Observational 30, Not applicable 22, Phase 4 15, Phase 3 25, Phase 2/3 5, Phase 2 29, Phase 1/2 3, Phase 1 8) 2003: 158 trials (Other 1, Observational 31, Not applicable 26, Phase 4 21, Phase 3 23, Phase 2/3 2, Phase 2 30, Phase 1/2 7, Phase 1 17) 2004: 215 trials (Other 2, Observational 39, Not applicable 26, Phase 4 30, Phase 3 39, Phase 2/3 6, Phase 2 40, Phase 1/2 9, Phase 1 24) 2005: 269 trials (Observational 53, Not applicable 32, Phase 4 45, Phase 3 37, Phase 2/3 6, Phase 2 51, Phase 1/2 13, Phase 1 32) 2006: 249 trials (Observational 42, Not applicable 35, Phase 4 35, Phase 3 34, Phase 2/3 6, Phase 2 41, Phase 1/2 16, Phase 1 40) 2007: 275 trials (Observational 52, Not applicable 43, Phase 4 33, Phase 3 45, Phase 2/3 9, Phase 2 37, Phase 1/2 18, Phase 1 38) 2008: 288 trials (Observational 62, Not applicable 56, Phase 4 50, Phase 3 29, Phase 2/3 5, Phase 2 38, Phase 1/2 10, Phase 1 38) 2009: 346 trials (Observational 84, Not applicable 52, Phase 4 45, Phase 3 30, Phase 2/3 6, Phase 2 65, Phase 1/2 13, Phase 1 51) 2010: 270 trials (Observational 65, Not applicable 46, Phase 4 31, Phase 3 29, Phase 2/3 1, Phase 2 35, Phase 1/2 18, Phase 1 45) 2011: 234 trials (Observational 51, Not applicable 43, Phase 4 27, Phase 3 35, Phase 2/3 5, Phase 2 20, Phase 1/2 13, Phase 1 40) 2012: 182 trials (Other 1, Observational 46, Not applicable 53, Phase 4 11, Phase 3 21, Phase 2/3 6, Phase 2 18, Phase 1/2 7, Phase 1 19) 2013: 197 trials (Observational 42, Not applicable 62, Phase 4 14, Phase 3 15, Phase 2/3 5, Phase 2 20, Phase 1/2 12, Phase 1 27) 2014: 204 trials (Observational 40, Not applicable 45, Phase 4 14, Phase 3 22, Phase 2/3 5, Phase 2 22, Phase 1/2 15, Phase 1 41) 2015: 228 trials (Observational 50, Not applicable 70, Phase 4 18, Phase 3 16, Phase 2/3 2, Phase 2 19, Phase 1/2 7, Phase 1 46) 2016: 224 trials (Observational 36, Not applicable 75, Phase 4 16, Phase 3 25, Phase 2/3 7, Phase 2 18, Phase 1/2 9, Phase 1 38) 2017: 278 trials (Observational 61, Not applicable 114, Phase 4 19, Phase 3 14, Phase 2/3 1, Phase 2 17, Phase 1/2 12, Phase 1 40) 2018: 271 trials (Observational 69, Not applicable 101, Phase 4 25, Phase 3 14, Phase 2/3 3, Phase 2 15, Phase 1/2 13, Phase 1 31) 2019: 297 trials (Observational 72, Not applicable 120, Phase 4 16, Phase 3 18, Phase 2/3 2, Phase 2 24, Phase 1/2 8, Phase 1 37) 2020: 263 trials (Observational 72, Not applicable 90, Phase 4 23, Phase 3 17, Phase 2/3 3, Phase 2 27, Phase 1/2 6, Phase 1 25) 2021: 291 trials (Observational 77, Not applicable 112, Phase 4 25, Phase 3 15, Phase 2/3 2, Phase 2 29, Phase 1/2 5, Phase 1 26) 2022: 277 trials (Observational 69, Not applicable 119, Phase 4 15, Phase 3 14, Phase 2/3 4, Phase 2 17, Phase 1/2 8, Phase 1 31) 2023: 251 trials (Observational 60, Not applicable 119, Phase 4 16, Phase 3 12, Phase 2/3 2, Phase 2 18, Phase 1/2 6, Phase 1 18) 2024: 215 trials (Observational 53, Not applicable 96, Phase 4 9, Phase 3 15, Phase 2/3 1, Phase 2 13, Phase 1/2 10, Phase 1 18) 2025: 178 trials (Observational 42, Not applicable 70, Phase 4 11, Phase 3 14, Phase 2/3 2, Phase 2 14, Phase 1/2 11, Phase 1 14)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 183
2025 178
2024 215
2023 251
2022 277
2021 291
2020 263
2019 297
2018 271
2017 278

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 381 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 4,477 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Immunologic Deficiency Syndromes trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,151
Phase 1/2 284
Phase 2 983
Phase 2/3 107
Phase 3 767
Phase 4 611
Not applicable 2,091
Observational 1,540
Expanded access 31

How many Immunologic Deficiency Syndromes trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 153
Recruiting 421
Enrolling by invitation 44
Active, not recruiting 193
Available 10

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Immunologic Deficiency Syndromes trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 1,141
ViiV Healthcare 248
National Cancer Institute (NCI) 91
Merck Sharp & Dohme LLC 90
ANRS, Emerging Infectious Diseases 87

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Immunologic Deficiency Syndromes? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Zidovudine 278
LAMIVUDINE 179
Efavirenz 144
Raltegravir 108
Nelfinavir 84

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ritonavir (RTV) low 164
didanosine, ddI (drug) 120
Stavudine 113
Nevirapine IR 109
Dolutegravir Pill 96

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Immunologic Deficiency Syndromes trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,382 244
Any Event in SOC 823 16
Gastroenteritis 744 146
Neutropenia 703 81
Road traffic accident 700 36

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Immunologic Deficiency Syndromes? (309)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Clinical and functional spectrum of RAC2-related immunodeficiency. Blood 2024 Yes
Interim analysis: Open-label extension study of leniolisib for patients with APDS. The Journal of allergy and clinical immunology 2024 Yes
Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Yes
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood 2024 Yes
High Frequency of Specific Polysaccharide Antibody Deficiency in Adults With Unexplained, Recurrent and/or Severe Infections With Encapsulated Bacteria. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Yes

Showing 5 of 309 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (14)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Primary immunodeficiency Point prevalence 1-9 / 100 000 United Kingdom GB Unspecified
Primary immunodeficiency Point prevalence 1-9 / 100 000 Australia Not stated Unspecified
Primary immunodeficiency Point prevalence 1-9 / 100 000 Netherlands Not stated Unspecified
Primary immunodeficiency Point prevalence 1-9 / 100 000 Spain Not stated Unspecified
Primary immunodeficiency Point prevalence 1-9 / 100 000 Norway Not stated Unspecified

Showing 5 of 14 prevalence observations.

Start your 14-day trial Email me all 14 prevalence observations as a PDF

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: rare-disease identity.

Browse all condition evidence pages